Viking Therapeutics (VKTX) Current Leases (2019 - 2025)
Viking Therapeutics' (VKTX) quarterly Current Leases came in at $137000.0 in Q4 2025, down 71.98% year-on-year from $489000.0 in Q4 2024, and down 68.65% quarter-over-quarter from $437000.0 in Q3 2025.
Viking Therapeutics (VKTX) Current Leases (2019 - 2025) Analysis & Trends
Viking Therapeutics has disclosed Current Leases across 7 years of filings, most recently posting $137000.0 for Q4 2025.
- Current Leases for Q4 2025 came in at $137000.0, down 71.98% year-over-year; the trailing twelve-month figure through Dec 2025 was $137000.0 (down 71.98% YoY), and the FY2025 annual result was $137000.0, down 71.98% from the prior year.
- Current Leases came in at $137000.0 for Q4 2025 at Viking Therapeutics, down from $437000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $498000.0 in Q1 2025 to a low of $29000.0 in Q4 2021.
- The 5-year median for Current Leases is $311500.0 (2023), against an average of $302500.0.
- Across the five-year window, Current Leases slumped 91.21% in 2021 and jumped 948.28% in 2022, its largest moves.
- Viking Therapeutics' Current Leases stood at $29000.0 in 2021, then surged by 948.28% to $304000.0 in 2022, then grew by 6.58% to $324000.0 in 2023, then surged by 50.93% to $489000.0 in 2024, then plunged by 71.98% to $137000.0 in 2025.
- The last three Current Leases figures came in at $137000.0 (Q4 2025), $437000.0 (Q3 2025), and $468000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Viking Therapeutics | 3.50 Bn | 3.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 437,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 489,000.00 |
| Sep 30, 2024 | 480,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 324,000.00 |
| Sep 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 314,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 304,000.00 |
| Sep 30, 2022 | 299,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 29,000.00 |
| Sep 30, 2021 | 115,000.00 |
| Jun 30, 2021 | 198,000.00 |
| Mar 31, 2021 | 279,000.00 |